Evidence map›Paper›PMID 31119819›Full record

ArticleCancer science2019

In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer.

Christoph Spartalis, Eva Marina Schmidt, Manal Elmasry, Gerald Bastian Schulz, Thomas Kirchner, David Horst

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. B7-H3 is spliced by SRSF3 in colorectal cancer.Cancer immunology, immunotherapy : CII · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Christoph SpartalisInstitute of Pathology, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Eva Marina SchmidtInstitute of Pathology, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Manal ElmasryInstitute of Pathology, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Gerald Bastian SchulzDepartment of Urology, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Thomas KirchnerInstitute of Pathology, Ludwig-Maximilians-Universität Munich, Munich, Germany.
David HorstInstitute of Pathology, Ludwig-Maximilians-Universität Munich, Munich, Germany.ORCID https://orcid.org/0000-0003-4755-5743
Ludwig-Maximilians-Universität München · DEGerman Cancer Research Center · DE

Funding

Deutsche Krebshilfe 111669Rudolf Bartling Stiftung
6 · The paper itself

Abstract

Patients with advanced colorectal cancer often are treated with systemic cytotoxic therapy using fluorouracil (5-FU), oxaliplatin, irinotecan, and FOLFOX or FOLFIRI combination protocols. Additionally, signaling pathways that are active in colorectal cancer can be therapeutically targeted. Herein, we examined whether chemotherapy impacts on WNT, MAPK and NOTCH signaling pathways in xenograft models of colon cancer. Furthermore, we tested whether combining chemotherapy with MAPK and NOTCH inhibition has superior therapeutic effects. We show that colon cancer cells with high WNT, MAPK and NOTCH activity are variably affected but generally persist in xenograft tumors under different chemotherapeutic regimens, indicating limited effects of cytotoxic therapy on oncogenic signaling pathways. Although these results provided a rationale to additionally target pathway activity, we found no significant increase in therapy response when combining MAPK and NOTCH inhibition with fluorouracil chemotherapy. We attribute this finding to a decrease in tumor cell proliferation upon MAPK and NOTCH inhibition, resulting in reduced effectiveness of cytotoxic treatment. Therapeutic benefits of combining chemotherapy with targeting of oncogenic signaling pathways must therefore be critically evaluated for patients with colorectal cancer.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCarcinogenesisCell ProliferationColorectal NeoplasmsFemaleFluorouracilHeterograftsHumansLeucovorinMaleMiceMice, Inbred NODMice, SCIDOncogenesOrganoplatinum CompoundsFluorouracilLeucovorinOrganoplatinum Compoundschemotherapycolon and colorectal cancerMAPKNOTCHWNT

Identifiers

PMID31119819
PMCPMC6676136
OpenAlexW2946477897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.